[{"orgOrder":0,"company":"Teoxane SA","sponsor":"Revance Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Revance Announces Transformative Aesthetics Portfolio Transaction with Exclusive U.S. Distribution Agreement of FDA-Approved Dermal Fillers from TEOXANE SA","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Agreement","leadProduct":"Hyaluronic Acid","moa":"Sodium channel alpha subunit","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Teoxane SA","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Teoxane SA \/ Revance Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Teoxane SA \/ Revance Therapeutics"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"American Regent","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"American Regent, Inc. to Acquire a Daiichi Sankyo Affiliate API Manufacturing Facility","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"JAPAN","productType":"Large molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Acquisition","leadProduct":"Polysulfated glycosaminoglycan","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Daiichi Sankyo \/ American Regent","highestDevelopmentStatusID":"12","companyTruncated":"Daiichi Sankyo \/ American Regent"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Bioiberica","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Strategic Distribution Between Bayer Animal Health and Bioiberica in the International Companion Animal Health Market","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Agreement","leadProduct":"Chondroitin Sulfate Sodium","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Bayer AG \/ Bioiberica","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/ Bioiberica"},{"orgOrder":0,"company":"Mithra Pharmaceuticals","sponsor":"Spirig Healthcare","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Mithra Signs LSA for Commercialization of Tibelia\u00ae in Liechtenstein and Switzerland","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Tibolone","moa":"Sulphatase","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Mithra Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Hormone","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mithra Pharmaceuticals \/ Spirig Healthcare","highestDevelopmentStatusID":"12","companyTruncated":"Mithra Pharmaceuticals \/ Spirig Healthcare"},{"orgOrder":0,"company":"Neurana Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurana Pharmaceuticals Announces First Patient Enrolled in CNS Effects Clinical Study","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Tolperisone","moa":"NaV Channel","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Neurana Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Neurana Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Neurana Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Amphastar Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amphastar Pharmaceuticals, Inc. Receives FDA Approval for Succinylcholine Chloride Injection USP, 200 mg\/10 mL (20 mg\/mL) Multiple-Dose Vial","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Succinylcholine Chloride","moa":"Muscle-type nicotinic acetylcholine receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Amphastar Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amphastar Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amphastar Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"SparingVision","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Pfenex Announces Enters New Partnership in Latin America, and Provides CRM197 Business Update","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"June 2020","year":"2020","type":"Agreement","leadProduct":"Teriparatide","moa":"PTH receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"SparingVision","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"SparingVision \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"SparingVision \/ Undisclosed"},{"orgOrder":0,"company":"Pfenex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfenex Announces Positive European CHMP Opinion for PF708","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Teriparatide","moa":"PTH receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Pfenex","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Pfenex \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfenex \/ Not Applicable"},{"orgOrder":0,"company":"Avadel Pharmaceuticals","sponsor":"Exela Pharma Sciences, LLC.","pharmaFlowCategory":"D","amount":"$42.0 million","upfrontCash":"$14.5 million","newsHeadline":"Avadel Sells Sterile Injectables Portfolio; will Focus on Narcolepsy","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Divestment","leadProduct":"Neostigmine Methylsulfate","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Avadel Pharmaceuticals","amount2":0.040000000000000001,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"Injection","sponsorNew":"Avadel Pharmaceuticals \/ Exela Sterile Medicines LLC","highestDevelopmentStatusID":"12","companyTruncated":"Avadel Pharmaceuticals \/ Exela Sterile Medicines LLC"},{"orgOrder":0,"company":"Ipsen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ipsen Announces Updated Indication for Dysport\u00ae (abobotulinumtoxinA) for the Treatment of Spasticity in Children","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Botulinum toxin type A","moa":"SNAP-25","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Ipsen","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Ipsen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ipsen \/ Not Applicable"},{"orgOrder":0,"company":"Unichem Laboratories Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Unichem Lab Gets USFDA Nod for Baclofen Tablets; Stock Ends Higher","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Baclofen","moa":"GABA B receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Unichem Laboratories Limited","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Unichem Laboratories Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Unichem Laboratories Limited \/ Not Applicable"},{"orgOrder":0,"company":"Antares Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Commercial Product Using Antares Pharma\u2019s Multi-Dose Pen Platform Launches in Europe","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Teriparatide","moa":"PTH receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Antares Pharma","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Antares Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Antares Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Mayne Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mayne Pharma Launches Chlorzoxazone Tablet in the United States","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Chlorzoxazone","moa":"Intermediate conductance calcium-activated potassium channel protein 4","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Mayne Pharma","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Mayne Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mayne Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Neurana Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurana Pharmaceuticals to Present Tolperisone Data at PAINWeek\u00ae National Conference","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Tolperisone","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Neurana Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Neurana Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Neurana Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Radius Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Radius Health: Enrollment Completed for Phase 3 wearABLe Trial","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Abaloparatide Acetate","moa":"PTH1 receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Radius Health","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Trabsdermal Patch","sponsorNew":"Radius Health \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Radius Health \/ Not Applicable"},{"orgOrder":0,"company":"Grunenthal","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Gr\u00fcnenthal Closes a Deal with Teva to Market Teriparatide","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"September 2020","year":"2020","type":"Agreement","leadProduct":"Teriparatide","moa":"PTH receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Grunenthal","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Grunenthal \/ Teva Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Grunenthal \/ Teva Pharmaceutical"},{"orgOrder":0,"company":"Eagle Pharmaceuticals","sponsor":"JPMorgan Chase Bank","pharmaFlowCategory":"D","amount":"$160.0 million","upfrontCash":"Undisclosed","newsHeadline":"Eagle Pharmaceuticals Commences $25 Million Accelerated Share Repurchase as Part of Existing $160 Million Share Repurchase Program","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Financing","leadProduct":"Dantrolene","moa":"RYR1","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Eagle Pharmaceuticals","amount2":0.16,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0.16,"dosageForm":"Intranasal","sponsorNew":"Eagle Pharmaceuticals \/ JPMorgan Chase Bank","highestDevelopmentStatusID":"12","companyTruncated":"Eagle Pharmaceuticals \/ JPMorgan Chase Bank"},{"orgOrder":0,"company":"Nexus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nexus Pharmaceuticals Receives FDA Approval for Succinylcholine Chloride Injection, USP","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Succinylcholine Chloride","moa":"Muscle-type nicotinic acetylcholine receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Nexus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nexus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Nexus Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy's Laboratories Announces the Launch of Succinylcholine Chloride Injection USP, 200 mg\/10 mL (20 mg\/mL) in the U.S. Market","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Succinylcholine Chloride","moa":"Muscle-type nicotinic acetylcholine receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Dr. Reddy\\\\\\'s Laboratories","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injection","sponsorNew":"Dr. Reddy\\\\\\'s Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dr. Reddy\\\\\\'s Laboratories \/ Not Applicable"},{"orgOrder":0,"company":"Neurana Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurana Pharmaceuticals Announces Publication in the Journal of Pain Research","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Tolperisone","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Neurana Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Neurana Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Neurana Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Regenxbio","sponsor":"Healthcare Royalty Management","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$200.0 million","newsHeadline":"Regenxbio Announces Agreement to Monetize Portion of Zolgensma\u00ae Royalties for $200 Million","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"December 2020","year":"2020","type":"Agreement","leadProduct":"Onasemnogene abeparvovec-xioi","moa":"SMN2 splicing","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Regenxbio","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Regenxbio \/ Healthcare Royalty Management","highestDevelopmentStatusID":"12","companyTruncated":"Regenxbio \/ Healthcare Royalty Management"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chugai's Osteoporosis Agent Edirol Obtains Regulatory Approval in China","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Eldecalcitol","moa":"Vitamin D3 receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Chugai Pharmaceutical","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Oral","sponsorNew":"Chugai Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Chugai Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lupin Launches Meloxicam Capsules","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Meloxicam","moa":"COX-2","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Lupin Ltd","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lupin Ltd \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lupin Ltd \/ Not Applicable"},{"orgOrder":0,"company":"Unichem Laboratories Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Celecoxib","moa":"COX-2","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Unichem Laboratories Limited","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Unichem Laboratories Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Unichem Laboratories Limited \/ Not Applicable"},{"orgOrder":0,"company":"Taisho Pharmaceutical","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Chugai Pharma, Taisho Pharma Terminate Co-Marketing Agreement for Edirol to Treat Osteoporosis","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Termination","leadProduct":"Eldecalcitol","moa":"Vitamin D3 receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Taisho Pharmaceutical","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Taisho Pharmaceutical \/ Chugai Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Taisho Pharmaceutical \/ Chugai Pharmaceutical"},{"orgOrder":0,"company":"Theramex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Theramex Launches Livogiva\u00ae, a New Teriparatide Pre-Filled Pen for the Treatment of Severe Osteoporosis London","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Biosimilar","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Teriparatide","moa":"PTH receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Theramex","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Solution for Injection in Pre-filled Pen","sponsorNew":"Theramex \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Theramex \/ Not Applicable"},{"orgOrder":0,"company":"NattoPharma","sponsor":"Gnosis by Lesaffre","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Gnosis by Lesaffre Enhances Vitamin K2 Offering with Acquisition of NattoPharma","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Acquisition","leadProduct":"Vitamin K2","moa":"SXR","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"NattoPharma","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"NattoPharma \/ Gnosis","highestDevelopmentStatusID":"12","companyTruncated":"NattoPharma \/ Gnosis"},{"orgOrder":0,"company":"Breckenridge Pharmaceutical","sponsor":"Aggrega Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Breckenridge Signs Multi-Product Agreement With Aggrega Pharma LLC","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Agreement","leadProduct":"Succinylcholine Chloride","moa":"Ach receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Breckenridge Pharmaceutical","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Breckenridge Pharmaceutical \/ Aggrega Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Breckenridge Pharmaceutical \/ Aggrega Pharma"},{"orgOrder":0,"company":"Abbott Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Abbott Gets CDSCO Approval for Marketing of Estradiol, Dydrogesterone FDC","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Estradiol","moa":"Estrogen receptor alpha","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Abbott Laboratories","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Hormone","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Abbott Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Abbott Laboratories \/ Not Applicable"},{"orgOrder":0,"company":"The Valens Company","sponsor":"Harvest One Cannabis","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"The Valens Agreement Manufacture and Distribute Leading Infused Topical Brand","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Agreement","leadProduct":"Capsaicin","moa":"TRPV1","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"The Valens Company","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"The Valens Company \/ Harvest One Cannabis","highestDevelopmentStatusID":"12","companyTruncated":"The Valens Company \/ Harvest One Cannabis"},{"orgOrder":0,"company":"Neurana Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurana Pharmaceuticals to Present at Napa Pain Conference and PAIN Week","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Tolperisone","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Neurana Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Neurana Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Neurana Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Cintex","sponsor":"Senores Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cintex Services, LLC and Senores Pharmaceuticals, Inc. Launch Chlorzoxazone Tablets USP, 250 mg in the U.S. Market","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Chlorzoxazone","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Cintex","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cintex \/ Senores Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Cintex \/ Senores Pharmaceuticals"},{"orgOrder":0,"company":"GLAND PHARMA LIMITED","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gland Pharma Receives Tentative Approval for Sugammadex Injection","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Sugammadex Sodium","moa":"Sugammadex?rocuronium chelating complex","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"GLAND PHARMA LIMITED","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"GLAND PHARMA LIMITED \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GLAND PHARMA LIMITED \/ Not Applicable"},{"orgOrder":0,"company":"Neurana Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurana Pharmaceuticals Completes Patient Enrollment in Phase 3 RESUME-1 Study","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Tolperisone","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Neurana Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Neurana Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Neurana Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Radius Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Radius Announces Results from the wearABLe Trial Evaluating Abaloparatide Transdermal System in Postmenopausal Women with Osteoporosis","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Abaloparatide Acetate","moa":"PTH receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Radius Health","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Radius Health \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Radius Health \/ Not Applicable"},{"orgOrder":0,"company":"Saol therapeutics","sponsor":"Amneal Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Amneal Acquires Saol Therapeutics\u2019 Baclofen Franchise","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Acquisition","leadProduct":"Baclofen","moa":"GABA B receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Saol therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Saol therapeutics \/ Amneal Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Saol therapeutics \/ Amneal Pharmaceuticals"},{"orgOrder":0,"company":"Medis","sponsor":"Lupin Ltd","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lupin Signs Distribution Agreement with Medis for Orphan Drug NaMuscla\u00ae","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Agreement","leadProduct":"Mexiletine","moa":"Sodium channel alpha subunits","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Medis","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medis \/ Lupin","highestDevelopmentStatusID":"12","companyTruncated":"Medis \/ Lupin"},{"orgOrder":0,"company":"BriOri BioTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BriOri BioTech Inc. Granted Patent for Topical Formulation of Rofecoxib","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Rofecoxib","moa":"COX-2","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"BriOri BioTech","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical","sponsorNew":"BriOri BioTech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BriOri BioTech \/ Not Applicable"},{"orgOrder":0,"company":"Q BioMed","sponsor":"Chengdu Syncor Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Q BioMed Announces Initial $500k Order of Strontium89 to Chinese Market","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Agreement","leadProduct":"Strontium-89 Chloride","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Q BioMed","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Radiolabelled Compound","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Q BioMed \/ Chengdu Syncor Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Q BioMed \/ Chengdu Syncor Pharmaceutical"},{"orgOrder":0,"company":"Neurana Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurana Pharmaceuticals Seeks Strategic Alternatives Following Phase 3 Study","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Tolperisone","moa":"NaV Channel","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Neurana Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Neurana Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Neurana Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sandoz, Inc. Issues Nationwide Recall of 13 Lots of Orphenadrine Citrate 100 mg Extended Release Tablets Due to Presence of a Nitrosamine Impurity","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Orphenadrine","moa":"H1 receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Sandoz B2B","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Extended Release Tablet","sponsorNew":"Sandoz B2B \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sandoz B2B \/ Not Applicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New UCB Data Analysis Adds to Demonstrated Efficacy of Romosozumab to Reduce the Risk of Fractures","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Romosozumab","moa":"Sclerostin","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"UCB Pharma S.A","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"UCB Pharma S.A \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UCB Pharma S.A \/ Not Applicable"},{"orgOrder":0,"company":"BriOri BioTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gordon Robert Alton, PhD Joins BriOri BioTech as COO to Develop Patented Topical Formulation of Vioxx\u00ae Providing Those Suffering with Osteoarthritis a Long Lasting Non-Opioid Option for Pain Relief","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Rofecoxib","moa":"COX-2","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"BriOri BioTech","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"BriOri BioTech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BriOri BioTech \/ Not Applicable"},{"orgOrder":0,"company":"Amazentis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Milestone Clinical Study Shows Postbiotic Urolithin A (Mitopure\u2122) Improves Muscle Strength and Exercise Performance in Middle Aged Adults","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Urolithin A","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Amazentis","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Amazentis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amazentis \/ Not Applicable"},{"orgOrder":0,"company":"Bioiberica","sponsor":"ByHealth","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"New Partnership With ByHealth in China","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Partnership","leadProduct":"Undenatured Type II Collagen","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Bioiberica","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bioiberica \/ ByHealth","highestDevelopmentStatusID":"12","companyTruncated":"Bioiberica \/ ByHealth"},{"orgOrder":0,"company":"Bioiberica","sponsor":"Apsen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bioiberica and Apsen Reinforce Partnership with New Holistic Mobility Product\u2013Motilex HA","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Partnership","leadProduct":"Hyaluronic Acid","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Bioiberica","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Bioiberica \/ Apsen","highestDevelopmentStatusID":"12","companyTruncated":"Bioiberica \/ Apsen"},{"orgOrder":0,"company":"Bioiberica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Study Reveals Bioiberica's Dermial\u00ae Delivers Superior Benefits for Skin Health","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Hyaluronic Acid","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Bioiberica","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bioiberica \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bioiberica \/ Not Applicable"},{"orgOrder":0,"company":"Bioiberica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Study Further Validates Bioiberica\u2019s B-2cool\u00ae Native Type II Collagen as Trusted Source for Holistic Mobility Solutions","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"chondroitin sulphate","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Bioiberica","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bioiberica \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bioiberica \/ Not Applicable"},{"orgOrder":0,"company":"Bioiberica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bioiberica Rebrands Its Range of Nutraceutical Ingredients for Healthcare","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Chondroitin Sulfate Sodium","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Bioiberica","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Bioiberica \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bioiberica \/ Not Applicable"},{"orgOrder":0,"company":"Bioiberica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Laboratorios Ordesa Incorporates B-2cool\u00ae, Bioiberica\u2019s Native Type II Collagen, in Its New Colnatur\u00ae Forte","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Harpagophytum Procumbens Extract","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Bioiberica","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bioiberica \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bioiberica \/ Not Applicable"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amneal Launches LYVISPAH\u00ae (baclofen) for Spasticity Related to Multiple Sclerosis and Other Spinal Cord Disorders","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Baclofen","moa":"PMP22 gene overexpression","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Amneal Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Granule","sponsorNew":"Amneal Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amneal Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Healthy Extracts","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Healthy Extracts\u2019 WHITNEY JOHNS ACTIVE\u2122 Clinically Proven to Enhance Physical Performance by Increasing Nitric Oxide by 73% and Oxygen Consumption by 24%","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"choline","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Healthy Extracts","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Healthy Extracts \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Healthy Extracts \/ Not Applicable"},{"orgOrder":0,"company":"Accord healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Accord's SONDELBAY\u00ae (teriparatide) is Given Green Light by CHMP","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Biosimilar","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Teriparatide","moa":"PTH1R","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Accord healthcare","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Accord healthcare \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Accord healthcare \/ Not Applicable"},{"orgOrder":0,"company":"Radius Health","sponsor":"Gurnet Point Capital","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Gurnet Point Capital and Patient Square Capital Complete Their Acquisition of Radius Health, Inc.","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"August 2022","year":"2022","type":"Acquisition","leadProduct":"Abaloparatide Acetate","moa":"PTH1 receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Radius Health","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0.89000000000000001,"dosageForm":"Injectable\/Injection","sponsorNew":"Radius Health \/ Gurnet Point Capital","highestDevelopmentStatusID":"12","companyTruncated":"Radius Health \/ Gurnet Point Capital"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Towa Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chugai Obtains Regulatory Approval for Osteoporosis Treatment Edirol Tablet","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Eldecalcitol","moa":"Vitamin D3 receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Chugai Pharmaceutical","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Chugai Pharmaceutical \/ Towa Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Chugai Pharmaceutical \/ Towa Pharmaceutical"},{"orgOrder":0,"company":"Radius Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Radius Health Update on Abaloparatide Transdermal System","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Abaloparatide Acetate","moa":"PTH1 receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Radius Health","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Radius Health \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Radius Health \/ Not Applicable"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kyowa Kirin Receives European Commission Approval for Use of CRYSVITA\u00ae (burosumab) for the Treatment of Tumour-Induced Osteomalacia (TIO)","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Burosumab","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Kyowa Kirin","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Kyowa Kirin \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Kyowa Kirin \/ Not Applicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ASBMR 2022: 3D Modelling of Hip DXA Scans in Postmenopausal Women With Osteoporosis Reveals Superior Improvements in Bone Density of Romosozumab Versus Controls","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Romosozumab","moa":"Sclerostin","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"UCB Pharma S.A","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"UCB Pharma S.A \/ Amgen Inc","highestDevelopmentStatusID":"12","companyTruncated":"UCB Pharma S.A \/ Amgen Inc"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Taisho Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Transfer and Future Marketing of Osteoporosis Agent Bonviva in Japan","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Ibandronate Sodium","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Chugai Pharmaceutical","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chugai Pharmaceutical \/ Taisho Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Chugai Pharmaceutical \/ Taisho Pharmaceutical"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lupin Launches Authorized Generic Version of PENNSAID\u00ae 2% w\/w in the United States","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Diclofenac Sodium","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Lupin Ltd","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"Lupin Ltd \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lupin Ltd \/ Not Applicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Towa Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chugai and Towa Launch Edirol Tablet for Osteoporosis Treatment","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Eldecalcitol","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Chugai Pharmaceutical","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chugai Pharmaceutical \/ Towa Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Chugai Pharmaceutical \/ Towa Pharmaceutical"},{"orgOrder":0,"company":"Radius Health","sponsor":"Gurnet Point Capital","pharmaFlowCategory":"D","amount":"$890.0 million","upfrontCash":"$547.0 million","newsHeadline":"Radius Health Announces Agreement to be Acquired by Gurnet Point Capital and Patient Square Capital","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"June 2022","year":"2022","type":"Acquisition","leadProduct":"Abaloparatide Acetate","moa":"PTH1 receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Radius Health","amount2":0.89000000000000001,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0.89000000000000001,"dosageForm":"Injectable\/Injection","sponsorNew":"Radius Health \/ Gurnet Point Capital","highestDevelopmentStatusID":"12","companyTruncated":"Radius Health \/ Gurnet Point Capital"},{"orgOrder":0,"company":"Radius Health","sponsor":"Gurnet Point Capital","pharmaFlowCategory":"D","amount":"$890.0 million","upfrontCash":"$547.0 million","newsHeadline":"Gurnet Point Capital and Patient Square Capital Complete Their Acquisition of Radius Health, Inc.","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"August 2022","year":"2022","type":"Acquisition","leadProduct":"Abaloparatide Acetate","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Radius Health","amount2":0.89000000000000001,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0.89000000000000001,"dosageForm":"Injectable\/Injection","sponsorNew":"Radius Health \/ Gurnet Point Capital","highestDevelopmentStatusID":"12","companyTruncated":"Radius Health \/ Gurnet Point Capital"},{"orgOrder":0,"company":"Radius Health","sponsor":"Theramex","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Theramex Enters Into an Exclusive Licensing Agreement With Radius Health Inc, to Commercialise ELADYNOS\u00ae \u25bcin the European Economic Area, the United Kingdom, Australia and Brazil","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"March 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Abaloparatide Acetate","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Radius Health","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Radius Health \/ Theramex","highestDevelopmentStatusID":"12","companyTruncated":"Radius Health \/ Theramex"},{"orgOrder":0,"company":"Mabwell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"The World's Second Approved Biosimilars of Denosumab (MAILISHU)","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Denosumab","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Mabwell","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Mabwell \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mabwell \/ Not Applicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus Lifesciences Gets Final Approval from The US FDA to Market Estradiol Transdermal System","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Estradiol","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Hormone","amount2New":0,"dosageForm":"Patch","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Lifesciences \/ Not Applicable"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sandoz Marketing Authorization Applications For Proposed Biosimilar Denosumab Accepted By EMA","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Denosumab","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Sandoz B2B","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sandoz B2B \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sandoz B2B \/ Not Applicable"},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ferring Announces Positive Topline Phase 3 Results for SI-6603, an Investigational Treatment for Lumbar Disc Herniation","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Condoliase","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Ferring Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Ferring Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ferring Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"EffRx Pharmaceuticals","sponsor":"Abiogen Pharma S.p.A","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Abiogen Pharma Completes the Acquisition of EffRx Pharmaceuticals","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Acquisition","leadProduct":"Alendronate Sodium","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"EffRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Effervescent","sponsorNew":"EffRx Pharmaceuticals \/ Abiogen Pharma S.p.A","highestDevelopmentStatusID":"12","companyTruncated":"EffRx Pharmaceuticals \/ Abiogen Pharma S.p.A"},{"orgOrder":0,"company":"Sanofi","sponsor":"CORONA remedies","pharmaFlowCategory":"D","amount":"$28.5 million","upfrontCash":"Undisclosed","newsHeadline":"CORONA Remedies Buys India's Ortho Brand Myoril","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Acquisition","leadProduct":"Thiocolchicoside","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Sanofi","amount2":0.029999999999999999,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0.029999999999999999,"dosageForm":"Capsule","sponsorNew":"Sanofi \/ CORONA remedies","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ CORONA remedies"},{"orgOrder":0,"company":"EffRx Pharmaceuticals","sponsor":"Radius Health","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"EffRx Pharmaceuticals Signs Exclusive Licensing Agreement with Radius Health to Commercialize BINOSTO\u00ae in the United States","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Alendronate Sodium","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"EffRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Effervescent","sponsorNew":"EffRx Pharmaceuticals \/ Radius Health","highestDevelopmentStatusID":"12","companyTruncated":"EffRx Pharmaceuticals \/ Radius Health"},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Stelis Receives a Positive Recommendation From European Medicines Agency (EMA) granting Market Authorization for KaulivTM, a Recombinant Human Teriparatide Biosimilar to Treat Osteoporosis","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Biosimilar","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Teriparatide","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Strides Pharma Science","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Strides Pharma Science \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Strides Pharma Science \/ Not Applicable"},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Strides Receives USFDA Approval for Pregabalin Capsules","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Pregabalin","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Strides Pharma Science","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Strides Pharma Science \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Strides Pharma Science \/ Not Applicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Teva Announces Approval of a Generic Version of Forteo\u00ae (teriparatide injection), in the U.S.","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Teriparatide","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Teva Pharmaceutical Industries","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Teva Pharmaceutical Industries \/ Not Applicable"},{"orgOrder":0,"company":"Ambio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ambio Announces US FDA Approval of a Generic Version of Forteo\u00ae (Teriparatide Injection) for Its Partner Apotex","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Teriparatide","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Ambio","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ambio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ambio \/ Not Applicable"},{"orgOrder":0,"company":"Apotex Fermentation Inc.","sponsor":"Ambio","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Apotex Corp. Launches Teriparatide Injectable for Osteoporosis Treatment in the United States","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Teriparatide","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Apotex Fermentation Inc.","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Apotex Fermentation Inc. \/ Ambio","highestDevelopmentStatusID":"12","companyTruncated":"Apotex Fermentation Inc. \/ Ambio"},{"orgOrder":0,"company":"Mabwell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MAIWEIJIAN, First Approved Biosimilar of Denosumab (120mg) in China","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Denosumab","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Mabwell","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mabwell \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mabwell \/ Not Applicable"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sandoz Gets EU Approval for Wyost\u00ae and Jubbonti\u00ae Denosumab Biosimilars","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Denosumab","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Sandoz B2B","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sandoz B2B \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sandoz B2B \/ Not Applicable"}]